Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ADAPTIN BIO, INC.NONE · Entity 9083 | Director | September 08, 2025 | September 10, 2025 |
| Athenex, Inc.ATNX · Entity 113753 | See Remarks | June 13, 2017 | August 21, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ADAPTIN BIO, INC.
Report date September 08, 2025 · Filed September 10, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.40 · Expires 2035-09-07 | Direct | 109,847 |
Reported balance
After 2025-09-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-09-08 · Grant · Acquired 109,847 · Balance 109,847 F1: The stock option vests in equal monthly installments on the last day of each calendar month over 48 months beginning on September 8, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests in equal monthly installments on the last day of each calendar month over 48 months beginning on September 8, 2025.
Athenex, Inc.
Report date June 13, 2017 · Filed August 21, 2018 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.00 · Expires 2027-06-13 | Direct | 120,000 |
Reported balance
After 2017-06-13 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2017-06-13 · Grant · Acquired 120,000 · Balance 120,000 F1: This option was previously reported by Mr. Riehle. This amendment is being filed to correct the transaction date, exercise date, and expiration date. F2: This option vests in three equal annual installments beginning on June 13, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was previously reported by Mr. Riehle. This amendment is being filed to correct the transaction date, exercise date, and expiration date.
F2: This option vests in three equal annual installments beginning on June 13, 2018.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 08, 2025 Filed Sep 10, 2025 21:00 UTC | ADAPTIN BIO, INC. NONE · Entity 9083 | GrantStock Option (right to buy) · Derivative | 109,847 | $0.00 Strike: $4.40 | $0.00 |
DisclosureSEC source: 0001213900-25-086586 · marketforms-70726.xml · derivative · entry 1 Riehle J Nick · CIK 0001316746 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,847 Underlying: Common Stock · 109,847 shares Expires 2035-09-07 F1 · derivative.exercise_date: The stock option vests in equal monthly installments on the last day of each calendar month over 48 months beginning on September 8, 2025. Read SEC document |
| June 19, 2017 Filed Jun 21, 2017 15:10 UTC | Athenex, Inc. ATNX · Entity 113753 | GrantStock Option (Right to Buy) · Derivative | 120,000 | $0.00 Strike: $11.00 | $0.00 |
DisclosureSEC source: 0000905148-17-000607 · form4.xml · derivative · entry 1 Riehle J Nick · CIK 0001316746 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2027-06-19 F1 · derivative.exercise_date: The option vests in three equal annual installments beginning on June 19, 2018. Read SEC document |
| June 19, 2017 Filed Jul 28, 2017 16:31 UTC Amendment | Athenex, Inc. ATNX · Entity 113753 | PurchaseCommon Stock | 1,500 | $11.00 | $16,500.00 |
DisclosureSEC source: 0000905148-17-000704 · form4.xml · nonDerivative · entry 1 Riehle J Nick · CIK 0001316746 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 F1 · shares: These shares of Common Stock ("Shares") were inadvertently omitted from the Reporting Person's Form 4 filed June 21, 2017. F2 · price: These Shares were purchased in the Issuer's initial public offering, which closed on June 19, 2017. Read SEC document |
| June 13, 2017 Filed Aug 21, 2018 18:07 UTC Amendment | Athenex, Inc. ATNX · Entity 113753 | GrantStock Option (Right to Buy) · Derivative | 120,000 | $0.00 Strike: $11.00 | $0.00 |
DisclosureSEC source: 0001209191-18-047824 · doc4a.xml · derivative · entry 1 Riehle J Nick · CIK 0001316746 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2027-06-13 F1 · date: This option was previously reported by Mr. Riehle. This amendment is being filed to correct the transaction date, exercise date, and expiration date. F1 · derivative.exercise_date: This option was previously reported by Mr. Riehle. This amendment is being filed to correct the transaction date, exercise date, and expiration date. F2 · derivative.exercise_date: This option vests in three equal annual installments beginning on June 13, 2018. F1 · derivative.expiration_date: This option was previously reported by Mr. Riehle. This amendment is being filed to correct the transaction date, exercise date, and expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.